News | Proton Therapy | February 10, 2020

Global Radiation Therapy Market to Reach $8.6B by 2026

Growing prevalence of cancer behind high demand for radiation therapy, but high costs to restraint market from reaching full potential

The radiation therapy market is projected to grow in through 2026

Image courtesy of Accuray

February 10, 2020 — Amid technological advancement, and notable research and development activities, the global radiation therapy market is set to chart a sturdy growth curve, owing to a steady growth rate of 5.2 percent from 2018 to 2026, according to a newly released report. As per Transparency Market Research (TMR), the growth is attributable to surge in product approvals, increase in expenditure on healthcare, high incidence of cancer, and a growing preference for non-invasive treatment procedures.

TMR states that, "From bench to clinic, there is a wave of therapeutic and diagnostic technologies, paving way for higher growth in oncology. And, this will aid radiation therapy witness better times to come. Over the forecast period external beam radiation therapy will dominate the market landscape."

Key Findings of the Radiation Therapy Market Study

  • Hospitals to dominate the end-user segment over the forecast period owing to robust infrastructure with state of the art-equipment and services usually available
  • External beam radiation therapy demand to account for a huge share owing to a stream of notable approvals and significant advancement in technology
  • Emerging economies to witness increase in need for radiation therapy owing to increase in incidence of cancer and growing awareness regarding the same; India and China to dominate regional demand curve

Radiation Therapy Market: Key Driving Factors

The market report, based on extensive research by Transparency Market Research, is leading to growth in the landscape. And, a wave of innovation is keeping the statistics buoyant over the period. Some of the factors that will sustain growth over the forecast period in the global radiation therapy market include the following:

  • Every year 439.2 people out of 100,000 add to the already huge pool of cancer patients worldwide and out of these 163.5 die each year
  • In United States alone, in 2018, 609,640 will die out of 1,735,350 people diagnosed with cancer
  • Approvals for products such as MRIdian Linac system, created by ViewRay, Inc., in 2017 is aiding the market chart high growth over the forecast period
  • Owing to high contribution from the United States of America, which is a large market of radiation therapy, North American region will dominate market landscape

Key Impediments for Radiation Therapy Market Players

While the overall outlook of the global radiation therapy market is positive, TMR speaks of certain restraints that will hamper growth to some extent. According to the study, the key restraints impeding market growth include,

  • High cost of treatment – unaffordable for a large chunk of people in the developing region, particularly in countries where healthcare cover is particularly low
  • Low awareness levels – Patients sometime are not aware of cancer cells wreaking havoc in the body till too late, this leads to late diagnosis
  • Radiation takes a toll on the body and the side effects make it difficult to tolerate for some patients

Radiation Therapy Market: Region-wise Analysis

  • One of the biggest revenue generators in the global radiation therapy market is the Asia Pacific region with Japan, China, and India, leading the way, credit rising levels of disposable income, and improving healthcare infrastructure
  • In countries such as India, expenses towards healthcare are increased and an effort to provide insurance cover to more and more people is set to contribute positively to regional growth
  • Large patient pool in the region and increasing awareness related to cancer symptoms and diagnosis is also a positive factor, promising to help the region chart significant growth  

Competitive Landscape

Strategic alliances and a keen focus on technological advancement is the key to growth for players operating in the global radiation therapy market over the forecast period. One of the most notable agreement that took place in the recent past – November 2018 – is that between Chengdu Xingcheng and Mevion. The aim behind the move is to lead center for proton therapy in China's sub-provincial city – Chengdu.

Besides, players are focused on product development and launch. For instance, in the year 2018, ProBeam 360 – a system of single room proton therapy - was launched by Varian Medical Systems. In the same year Hitachi Ltd. received approval for commercialization of RGPT.

Key players include Varian Medical Systems, Inc. (US), Elekta (Sweden), Accuray Incorporated (US), Ion Beam Applications SA (Belgium), ViewRay, Inc. (US), IsoRay Medical, Inc. (US), Hitachi Ltd. (Japan), Panacea Medical Technologies Pvt. Ltd. (India), Provision Healthcare (US), and Mevion Medical Systems, Inc. (US)

By Type:

External beam Radiation Therapy

  • Conformal Radiation Therapy
  • Proton Beam Therapy
  • Image Guided Radiation Therapy
  • Stereotactic Radiation Therapy

Internal Radiation Therapy

  • Brachytherapy
  • Systemic Radiation Therapy

By End user:

  • Hospitals
  • Specialty Clinics

For more information: www.transparencymarketresearch.com

Related Content

#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 Professor David Sebag-Montefiore (Image courtesy of the University of Leeds)

Professor David Sebag-Montefiore (Image courtesy of the University of Leeds)

News | Radiation Therapy | April 07, 2020
April 7, 2020 — An intern...
Eclipse v16 has received CE mark and is 510(k) pending
News | Proton Therapy | April 06, 2020
April 6, 2020 — Driven by its Intelligent Cancer Care approach in developing new solutions that use advanced technolo
Varian received FDA clearance for its Ethos therapy in February 2020. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Varian received FDA clearance for its Ethos therapy in February 2020, shown here displayed for the first time at ASTRO 2019. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Feature | Treatment Planning | April 03, 2020 | Dave Fornell, Editor
The traditional treatment planning process takes days to create an optimized radiation therapy delivery plan, but new
A new framework from an international team of experts aims to help protect patients and providers, and conserve protective equipment for frontline healthcare workers #COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2
News | Prostate Cancer | March 30, 2020
March 30, 2020 — In the wake of the COVID-19 pan
Women are more likely to be cured of cancer by radiotherapy but the side effects are worse.

Women are more likely to be cured of cancer by radiotherapy but the side effects are worse. Image by Mark Kostich

News | Radiation Therapy | March 30, 2020
March 30, 2020 — Women undergoing radiotherapy for
Novel scanners may open door for prognostic assessment in patients receiving cochlear implants

Iva Speck, MD, explains research showing that novel, fully digital, high-resolution positron emission tomography/computed tomography imaging of small brain stem nuclei can provide clinicians with valuable information concerning the auditory pathway in patients with hearing impairment. The research is featured in The Journal of Nuclear Medicine (read more at http://jnm.snmjournals.org/content/current). Video courtesy of Iva Speck, University Hospital Freiburg, Germany.

News | PET-CT | March 26, 2020
March 26, 2020 — Novel, fully digital, high-resolution...
Age‐standardized, delay‐adjusted overall cancer incidence rates for 2012 through 2016 are illustrated among males and females by racial/ethnic group

Age‐standardized, delay‐adjusted overall cancer incidence rates for 2012 through 2016 are illustrated among males and females by racial/ethnic group. Racial/ethnic groups are mutually exclusive. Data for the non‐Hispanic American Indian/Alaska Native (AI/AN) population are restricted to Indian Health Service Purchased/Referred Care Delivery Area (PRCDA) counties. API indicates Asian/Pacific Islander. Chart courtesy of ACS Journals 

News | Radiation Oncology | March 16, 2020
March 16, 2020 — The Ann...